Matinas BioPharma oral LNC-docetaxel shows no toxicity in mouse study; 8x higher dose tolerated without weight loss

Matinas BioPharma Holdings, Inc.

Total docetaxel delivered orally via LNC was >8x IV dose by Day 22; all IV mice lost avg 20% weight, LNC mice maintained weight normal.
One IV-docetaxel mouse died (32% weight loss); LNC-docetaxel mice had no mortality and weight statistically same as saline controls.
Daily oral LNC-docetaxel dose 50% higher and total drug 3.5x greater than prior study that showed comparable anti-tumor activity to IV-docetaxel.
Company plans further evaluation of higher doses in additional tumors and other toxic chemotherapies using LNC platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.